Abstract | AIM: METHODS: RESULTS: The eradication rates in the rabeprazole- amoxicillin- clarithromycin (RAC) and lansoprazole- amoxicillin- clarithromycin (LAC) groups were 75% and 69%, respectively, on an intention-to-treat basis, and 80% and 75%, respectively, on a per protocol basis. The eradication rate for clarithromycin-resistant strains was significantly lower than that for clarithromycin-sensitive strains (24% vs. 86%, P < 0.05). For clarithromycin-sensitive strains in the LAC group, there was a tendency for a lower eradication rate in extensive than poor metabolizers. The eradication rate in extensive metabolizers in the RAC group tended to be higher than that in extensive metabolizers in the LAC group (89% vs. 78%, P = 0.079726). CONCLUSIONS:
|
Authors | H Kawabata, Y Habu, H Tomioka, H Kutsumi, M Kobayashi, K Oyasu, T Hayakumo, S Mizuno, K Kiyota, M Nakajima, K Kimoto, H Inokuchi, K Kawai |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 17
Issue 2
Pg. 259-64
(Jan 2003)
ISSN: 0269-2813 [Print] England |
PMID | 12534411
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- 2-Pyridinylmethylsulfinylbenzimidazoles
- Anti-Bacterial Agents
- Anti-Ulcer Agents
- Benzimidazoles
- Lansoprazole
- Rabeprazole
- Amoxicillin
- Cytochrome P-450 Enzyme System
- Clarithromycin
- Omeprazole
|
Topics |
- 2-Pyridinylmethylsulfinylbenzimidazoles
- Adult
- Aged
- Amoxicillin
(therapeutic use)
- Anti-Bacterial Agents
(therapeutic use)
- Anti-Ulcer Agents
(therapeutic use)
- Benzimidazoles
(therapeutic use)
- Clarithromycin
(therapeutic use)
- Cytochrome P-450 Enzyme System
(genetics)
- Drug Resistance
(genetics)
- Drug Therapy, Combination
(therapeutic use)
- Female
- Helicobacter Infections
(drug therapy, genetics)
- Helicobacter pylori
(genetics)
- Humans
- Lansoprazole
- Male
- Middle Aged
- Omeprazole
(analogs & derivatives, therapeutic use)
- Peptic Ulcer
(microbiology)
- Rabeprazole
- Treatment Outcome
|